Navigation Links
Oncothyreon reports second quarter 2009 financial results
Date:8/12/2009

s and Other Comprehensive Loss Data (in thousands except per share amounts) (unaudited) Three Months Ended Six Months Ended June 30 June 30 ------------------ ------------------ 2009 2008 2009 2008 -------- -------- -------- -------- Revenue Contract manufacturing......... - 802 - 2,520 Licensing revenue from collaborative agreements...... 4 350 8 652 Licensing, royalties and other revenue................. 27 - 27 - -------- -------- -------- -------- 31 1,152 35 3,172 -------- -------- -------- -------- Expenses Research and development....... 1,995 2,726 2,675 5,034 Manufacturing.................. - 646 - 2,726 General and administrative..... 1,745 2,661 3,496 5,364 Amortization................... 67 103 132 206 Investment and other income.... 54 (68) 34 (128) Change in fair value of warrant liability............. 2,502 - 2,502 - -------- -------- -------- -------- 6,363 6,068 8,839 13,202 -------- -------- -------- -------- Net loss......................... (6,332) (4,916) (8,804) (10,030) Other comprehensive income (loss).......................... - 72
'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program 2The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program 3Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6
Breaking Biology News(10 mins):Rodent smoke screen 2Plate-eating good: Université de Montréal professor designs edible tableware 2Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 1Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 2Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 3Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 4Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 5Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 1Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 2Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 3Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 4Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 5Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 6Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 7Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 8Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 9Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 10Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 11Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 12Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 13Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 14Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 15Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 16Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 17Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 18Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 19Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 20Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 21Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 22Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 23Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 24Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11